 |
关键词：
【摘要 】 目的 观察高血压病患者血小板活化状态和纤溶活性的变化并用缓释异搏定、开博通降压治疗后观察上述指标的变化。方法 采用发色底物法、放射免疫法检测对象为Ⅰ、Ⅱ期高血压病患者50例、正常对照者25例的组织型纤溶酶原激活剂(t-PA)及其抑制物(PAI-1)的活性，其中高血压病患者30例、正常对照者17例测定了活化血小板α颗粒膜蛋白(GMP-140)的含量。50例高血压病患者中21例接受缓释异搏定治疗，19例用开博通治疗，疗程12周。结果 高血压病患者PAI-1活性、GMP-140含量较正常高，t-PA活性低于正常；缓释异搏定和开博通降压治疗12周后，PAI-1活性、GMP-140含量下降，t-PA活性增强，与治疗前比，差异有显著性(P值分别<0.05，0.01)。结论 提示Ⅰ、Ⅱ期高血压病患者血小板活化功能增强，纤溶活性降低。缓释异搏定和开博通均能在降压治疗的同时改善高血压病患者异常的血小板活化和纤溶活性。
Changes of GMP-140 and fibrinolytic activity in essential hypertension Dai Tiane, Sun Ming, Zhou Hongyan, et al. Department of Cardiology, The Affiliated Xiangya Hospital, Hunan Medical University, Changsha, 410008
【 Abstract 】 Objective To observe platelet activation and fibrinolytic activity in essential hypertension and study the effects of delayed-release verapamil and capoten on them. Methods Developing substrate method and radioimmunoassay were used to examine the activity of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in 50 hypertensives of stage Ⅰ to Ⅱ and 25 normotensives. Platelet alphagranule membrane protein (GMP-140) was studied in 30 hypertensives and 17 normotensives. Delayed-release veraparmil was used in 21 hypertensives and capoten in 19 hypertensives for 12 weeks. Results Elevated GMP-140, decreased t-PA activity and elevated PAI-1 activity were detected in hypertensives but not in normotensives. GMP-140 and PAI-1 activity were decreased, but t-PA activity was increased after treatment with delayed-release veraparmil and capoten respectively for 12 weeks. Conclusion There are elevated platelet activation and decreased fibrinolytic activity in stage Ⅰ to Ⅱ essential hypertensives. Both delayed-release verapamil and capoten can decrease blood pressure and at the same time ameliorate the abnormality of platelet activation and improve fibrinolytic activity in essential hypertension.
【 Key words 】 Hypertension Platelet activation Alteplase
近年来 ......
您现在查看是摘要页，全文长 16089 字符。